Table 3.
Spectrum of NTM Disease and Treatment
| Pt | Age (y) |
Gender | Diagnosis | Transplant type |
Days to infection diagnosis |
Days to disease diagnosis |
NTM species |
|---|---|---|---|---|---|---|---|
| 1 | 49 | F | IPF | BL | 614 | 614 | Abscessus |
| 2 | 53 | F | IPAH | BL | 323 | 323 | MAC |
| 3 | 55 | M | COPD | SL | 252 | 788 | MAC |
| 4 | 56 | F | SCL | BL | 8 | 487 | Abscessus |
| 5 | 70 | M | COPD | SL | 1 | 1 | MAC |
| 6 | 33 | M | SCL | BL | 583 | 583 | Abscessus |
| 7 | 56 | F | COPD | BL | 605 | 720 | MAC |
| 8 | 60 | M | IPAH | BL | 749 | 749 | Simaie |
| 9 | 57 | M | IPF | BL | 8 | 83 | Abscessus |
| Respiratory symptoms |
CT/CXR finding | Treatment | Duration (months) |
Response to treatment | Status/days post-operative |
|---|---|---|---|---|---|
| SOB, cough | Bilateral centrilobular nodularity | A, Ami, Imi→A | 12 | NTM clearance by 3 mo, progressive graft dysfunction | Dead/1,161 |
| Cough | Right centrilobular nodularity | C, ethambutol, rifabutin | 5 | NTM clearance by 3 mo, progressive graft dysfunction | Dead/452 |
| SOB, cough | RUL nodular opacity (native lung) | C, ethambutol, rifabutin | 18 | NTM clearance by 6 mo, complete resolution | Dead/1,606 |
| SOB | RLL centrilobular nodularity and consolidation | A, Ami, Imi→A | 24 | NTM clearance by 6 mo, complete resolution | Alive/2,109 |
| Post-operative | LUL nodular opacity (native lung) | A, ciprofloxacin | 12 | NTM clearance by 1 mo, complete resolution | Dead/1,185 |
| SOB, cough | RLL centrilobular nodularity and consolidation | C, Ami, tygecycline | 1 | Unknown NTM clearance, progressive graft dysfunction | Dead/612 |
| SOB, cough | Right centrilobular nodularity | A, ethambutol, ciprofloxacin→A | 12 | NTM clearance by 3 mo, progressive graft dysfunction | Alive/ 1,679 |
| SOB, pleurisy | LUL nodular opacity | A, moxifloxacin, rifabutin | 12 | NTM clearance by 3 mo, complete resolution | Alive/1,295 |
| Hypoxemia, cough | Clustered tree-in-bud centrilobular air-space nodularity | C, Ami | 9 | NTM clearance by 3 mo, progressive graft dysfunction | Dead/346 |
A, azithromycin; Ami, amikacin; BL, bilateral lung; C, clarithromycin; COPD, chronic obstructive pulmonary disease; F, female; Imi, imipenem; IPAH, idiopathic pulmonary arterial hypertension; IPF, idiopathic pulmonary fibrosis; LUL, left upper lobe; M, male; MAC, Mycobacterium avium complex; NTM, non-tuberculous mycobacterium; SCL, scleroderma; SL, single lung; SOB, shortness of breath; →, transitioned to.